Idenix Shares Plunge on Hepatitis C Treatment Heart Fears

Idenix Pharmaceuticals Inc. fell 30 percent after a trial of the company’s hepatitis C drug was placed on hold because of heart failure concerns raised in a competitor’s study of a similar medicine.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.